Changing perspective on immunization against influenza

Vaccine

Volumn 25, Issue 16 SPEC. ISS., 2007, Pages 3062-3065

  Johansson, Bert E ^a   Brett, Ian C ^b  

^a Innovation Sciences   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Influenza; Neuraminidase; Vaccine

Indexed keywords

INACTIVATED VIRUS VACCINE; LIVE VACCINE; VIRUS HEMAGGLUTININ; VIRUS SIALIDASE;

ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; INFLUENZA; NONHUMAN; PRIORITY JOURNAL; VACCINE PRODUCTION; VIRUS RECOMBINANT; WILD TYPE; YEAST;

EID: 33947582401     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.01.030     Document Type: Article

References (17)

1. Kilbourne E.D. Influenza (1987), Plenum Publishing, New York pp. 164-5
2. Neuman G., and Kawaoka Y. Host range restriction and pathogenicity in the context of influenza pandemic. Emerg Infect Dis 12 6 (2006) 881-886
3. Kilbourne E.D., Cerini C.P., Khan M.W., Mitchell Jr. J.W., and Ogra P.O. Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. Studies in human vaccines. J Immuno 138 (1987) 3010
4. Brett I.C., and Johansson B.E. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 339 (2005) 273-280
5. McMicheal A., Grotch F., Cullen P., Askonas B., and Webster R. The human cytotoxic T cell response to influenza vaccination. Clin Exp Immunol 43 (1981) 276
6. McLaren C., Verbonitz M.W., Daniel S., Guggs G., and Ennis F. Effect of priming infection on serologic response to whole and subunit influenza virus vaccines in animals. J Immuno 125 (1977) 2679
7. Kilbourne E., Grajower B., and Johansson B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase. Proc Natl Acad Sci USA 87 (1990) 786-790
8. Hoskins T.W., Davies J.R., Smith A.J., Miller C.L., and Allchin A. Assessment of inactivated influenza A vaccine after three outbreaks of influenza at Christ's Hospital. Lancet 1 (1979) 33
9. Belshe R., Gruber W., Mendelman P., Cho I., Reisinger K., Block S., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136 2 (2000) 168-175
10. Johansson B., Moran T., and Kilbourne E. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Natl Acad Sci USA 84 (1987) 6869
11. Hocart M., Grajower B., Donabedian A., Pokorny B., Whitaker C., and Kilbourne E. Preparation and characterization of a purified influenza virus neuraminidase vaccine. Vaccine 13 (1995) 1793
12. Schiff G., Kilbourne E., Smith G., Hackett C., Manoff S., and Matthews J. Phase 2 clinical evaluation of an influenza A virus recombinant N2 neuraminidase. The First European Influenza Congress Hersonessos. Crete, Greece, 23-28 September (2000)
13. Treanor J.J., Schiff G.M., Couch R.B., Cate T.R., Brady R.C., Hay C.M., et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus. J Infect Dis 193 (2006) 1223
14. Powers D.C., Smith G.E., Anderson E.L., Kennedy D.J., Hackett C.S., Wilkinson B.E., et al. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J Infect Dis 173 June (6) (1996) 1467-1470
15. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New England J Med 354 13 (2006) 1343-1351
16. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19 (2001) 1732-1737
17. Chen Z., Matsuo K., Asanuma H., Takahashi H., Iwasaki T., Suzuki Y., et al. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Vaccine 17 (1999) 653-655